Track topics on Twitter Track topics that are important to you
The company has also expanded its headquarters and device development facilities, which are now located in Cambourne Business Park, also in Cambridge. PlaqueTec is leading biomarker-based cardiovascul...
Distinguished faculty of about 75-100 global cardiology leaders meet by invitation only to advance the study and practice of atherosclerosis PlaqueTec announced today that it ...
PlaqueTec plans to bring precision medicine to cardiovascular prevention with a catheter technology that enables biomarker discovery.
PlaqueTec Ltd. has relocated its existing coronary plasma bank from Royal Papworth Hospital to the communal laboratory facility within the Babraham Research Campus in Cambridge. ...
Analysis of intracoronary blood samples obtained via PlaqueTec’s Liquid Biopsy System suggests coronary inflammation may be independent of systemic inflammatory biomarkers ...
This interventional study is using the PlaqueTec LBS will enrol participants already undergoing coronary angiography as a component of their standard care for NSTE-ACS. The study will invo...
PlaqueTec offers a first-of-its-kind catheter technology for cardiologists to routinely assess inflammation in the coronary artery, and better understand residual inflammatory ris...
We have published hundreds of PlaqueTec Ltd. news stories on BioPortfolio along with dozens of PlaqueTec Ltd. Clinical Trials and PubMed Articles about PlaqueTec Ltd. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of PlaqueTec Ltd. Companies in our database. You can also find out about relevant PlaqueTec Ltd. Drugs and Medications on this site too.